The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics
Under the agreement, Technology Development Board and Bharat Biotech have pledged the support of Rs.200 crore each to create a continuous corpus of Rs.400 crores for the project
The vaccine is designed to neutralise the virus in the nostril itself and prevent it from penetrating deep down into the respiratory tract
This is the first of its kind vaccine for Covid 19 to get the go-ahead
Subscribe To Our Newsletter & Stay Updated
